Correction to: Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series

Jessica Atieh¹ · Jordan Sack^{2,3} · Richard Thomas^{3,4} · Osama E. Rahma^{3,5} · Michael Camilleri¹ · Shilpa Grover^{2,3}

Published online: 7 August 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Digestive Diseases and Sciences
<https://doi.org/10.1007/s10620-020-06440-x>

The original version of the article unfortunately contained an error in the Table 2. In the column ‘Motility immune-related adverse event’ of Table 2, the term ‘Intestinal

pseudo-obstruction’ was inadvertently removed in the final version. Corrected Table 2 is given below.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s10620-020-06440-x>.

✉ Michael Camilleri
camilleri.michael@mayo.edu

¹ Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) and Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. S.W., Rochester, MN, USA

² Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Boston, MA, USA

³ Harvard Medical School, Boston, MA, USA

⁴ Department of Radiology, Brigham and Women’s Hospital, Boston, MA, USA

⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA, USA

Table 2 Prior case reports of patients with gastrointestinal Motility immune-related adverse event

Motility immune-related adverse event	Age, years	Gender	ICI	Target	Tumor	References
Intestinal pseudo-obstruction	57	Male	Pembrolizumab	PD-1	Neuroendocrine	[17]
	62	Male	Nivolumab	PD-1	NSCLC	[35]
	71	Female	Pembrolizumab	PD-1	GEJ carcinoma	[25]
Constipation	62	Male	Ipilimumab	CTLA-4	Melanoma	[20]
Ileus	66	Male	Ipilimumab + nivolumab	CTLA-4 + PD-1	Merkel cell carcinoma	[19]

PD-1 programmed death-1, *NSCLC* non-small cell lung cancer, *GEJ* gastroesophageal junction

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.